Showing results (41-50 of 60) with videos related to
Sort By:
Pageof 6
Leukemia & Lymphoma|January 24, 2020
Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FLPaolo Strati, Mohamed Amin Ahmed, Loretta J Nastoupil, et al.Blood Advances|March 31, 2022
SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximabMario L Marques-Piubelli, Edwin R Parra, Lei Feng, et al.Blood Advances|May 1, 2019
Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphomaChelsea C Pinnix, Sarah A Milgrom, Chan Yoon Cheah, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2018
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN StudyAjay K Gopal, Stephen J Schuster, Nathan H Fowler, et al.The Lancet. Oncology|December 3, 2014
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan H Fowler, R Eric Davis, Seema Rawal, et al.British Journal of Haematology|December 17, 2016
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphomaDai Chihara, Michelle A Fanale, Roberto N Miranda, et al.Blood|May 5, 2022
Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphomaHua-Jay J Cherng, Ryan Sun, Bryant Sugg, et al.Leukemia & Lymphoma|May 10, 2017
Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphomaJennifer C Ho, Bouthaina S Dabaja, Sarah A Milgrom, et al.Cancer Discovery|March 26, 2026
Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid TumorsBurak Uzunparmak, Fei Su, Amber Johnson, et al.Cancer|November 20, 2023
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 studyMax J Gordon, Lei Feng, Paolo Strati, et al.Pageof 6